Related Experiment Video

Updated: Jul 24, 2025

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

10.2K

Immune Checkpoint Inhibitor-Induced Lymphocytic Esophagitis

Shefali Amin1, Salina Munankami2, Parth Desai3

  • 1Internal Medicine, Reading Hospital/Tower Health, West Reading, USA.

Cureus
|July 6, 2023
PubMed

Insights

This case report details a rare instance of lymphocytic esophagitis, an immune-related toxicity associated with immune checkpoint inhibitors (ICIs) like nivolumab. It highlights the importance of recognizing this condition in patients undergoing cancer immunotherapy.

Area of Science:

  • Oncology
  • Immunology
  • Gastroenterology

Background:

  • Immune checkpoint inhibitors (ICIs) are vital in treating advanced cancers.
  • ICI therapy can cause immune-related adverse events, including gastrointestinal toxicities.

Observation:

  • A 79-year-old male with metastatic renal clear cell carcinoma on nivolumab presented with dysphagia.
  • Endoscopic evaluation revealed esophagitis, with biopsies showing lymphocytic infiltration, dyskeratosis, and acanthosis.

Findings:

  • The histological findings were consistent with nivolumab-associated lymphocytic esophagitis.
  • This represents a rare immune-related toxicity of ICI therapy.

Implications:

  • Early recognition and diagnosis of ICI-induced esophagitis are crucial for patient management.
  • Further research is needed to establish optimal treatment strategies for this rare condition.

Keywords:
esophagitisici esophagitisimmune check-point inhibitorlymphocytic esophagitisnivolumab

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

448
Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

813

Related Concept Videos

Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
214
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
573
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
200